Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy L St Peter

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|October 17, 2009
Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services dataWendy L St Peter, Qiao Fan, Eric Weinhandl, et al.
Pharmacotherapy|June 26, 2013
Lower risk of major cardiovascular events associated with adherence to colesevelam HCIXin Ye, Chunlin Qian, Jiannong Liu, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 26, 2008
A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims dataWendy L St Peter, Jiannong Liu, Eric Weinhandl, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 20, 2013
Clinical outcomes associated with receipt of integrated pharmacy services by hemodialysis patients: a quality improvement reportEric D Weinhandl, Thomas J Arneson, Wendy L St Peter
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 3, 2017
Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and PoliciesWendy L St Peter, Lori D Wazny, Eric D Weinhandl
Pharmacotherapy|April 12, 2013
To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney diseaseWendy L St Peter, Lauren E Odum, Adam T Whaley-Connell
Hemodialysis International. International Symposium on Home Hemodialysis|December 19, 2008
Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison resultsWendy L St Peter, Jiannong Liu, Eric D Weinhandl, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 2, 2003
Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomesWendy L St Peter, Anton C Schoolwerth, Tracy McGowan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 27, 2005
Medication-related problems in ambulatory hemodialysis patients: a pooled analysisHarold J Manley, Carrie A Cannella, George R Bailie, et al.
Kidney Medicine|July 28, 2022
Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United StatesJulie Z Zhao, Eric D Weinhandl, Angeline M Carlson, et al.
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Clinical Journal of the American Society of Nephrology : CJASN|October 17, 2009
Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services dataWendy L St Peter, Qiao Fan, Eric Weinhandl, et al.
Pharmacotherapy|June 26, 2013
Lower risk of major cardiovascular events associated with adherence to colesevelam HCIXin Ye, Chunlin Qian, Jiannong Liu, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 26, 2008
A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims dataWendy L St Peter, Jiannong Liu, Eric Weinhandl, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 20, 2013
Clinical outcomes associated with receipt of integrated pharmacy services by hemodialysis patients: a quality improvement reportEric D Weinhandl, Thomas J Arneson, Wendy L St Peter
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 3, 2017
Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and PoliciesWendy L St Peter, Lori D Wazny, Eric D Weinhandl
Pharmacotherapy|April 12, 2013
To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney diseaseWendy L St Peter, Lauren E Odum, Adam T Whaley-Connell
Hemodialysis International. International Symposium on Home Hemodialysis|December 19, 2008
Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison resultsWendy L St Peter, Jiannong Liu, Eric D Weinhandl, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 2, 2003
Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomesWendy L St Peter, Anton C Schoolwerth, Tracy McGowan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 27, 2005
Medication-related problems in ambulatory hemodialysis patients: a pooled analysisHarold J Manley, Carrie A Cannella, George R Bailie, et al.
Kidney Medicine|July 28, 2022
Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United StatesJulie Z Zhao, Eric D Weinhandl, Angeline M Carlson, et al.
Pageof 8